Valbiotis strengthens its CSR commitment by adhering to the United Nations Global Compact and by applying the ISO 26000 standard
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory news:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/PME eligible), a Research and Development company committed to scientific innovation to prevent and combat metabolic and cardiovascular diseases, is strengthening its commitment to Corporate Social Responsibility (CSR) ) by joining the United Nations Global Compact and applying the ISO 26000 standard.
The United Nations Global Compact brings together businesses, organizations, United Nations agencies, the professional world and civil society around 10 universally accepted principles to build more stable and inclusive societies. Framework of voluntary commitment, international reference, platform for action and exchange, the Global Compact is the largest global initiative for corporate social responsibility, with more than 19,000 participants in 170 countries.
Valbiotis, through its membership, supports the 10 principles of the United Nations Global Compact concerning respect for human rights, international labor standards, environmental protection and the fight against corruption.
With this new commitment, Valbiotis expresses its desire to strengthen and integrate these principles into its long-term strategy, its culture, its day-to-day operations, and to advance them in its area of influence. Valbiotis will also participate in projects advancing the broader development goals of the United Nations, in particular contributing to the achievement of the Sustainable Development Goals (SDGs).
Valbiotis has already committed to SDG 3 “Good health and well-being” and SDG 9 “Industry, innovation and infrastructure” by developing innovative plant active ingredients to prevent metabolic and cardiovascular diseases or to act on the states early pathologies.
During the first year of its membership in the Global Compact, Valbiotis undertakes to initiate actions on the following principles:
– Implementation of CSR governance, with the creation of a CSR steering committee reporting directly to the CEO of Valbiotis, the structuring of an approach in accordance with the ISO 26000 standard and the awareness of all of its employees.
– Assessment of the impact of its activities on the environment, and implementation of concrete actions to contribute to SDG 13 – Measures to combat climate change.
Sébastien Peltier, CEO and Chairman of the Board comments: “We are very proud to reinforce our commitment by joining the United Nations Global Compact, which marks a new stage in the growth and development of the Company beyond our public health mission focused on reducing the impact that metabolic and cardiovascular diseases can put millions of people at risk worldwide. It translates the ambition of the company, in its new dimension, to integrate the strategy of Corporate Social Responsibility into our priority areas of action, the commitments and the objectives that will take us forward. We structure our CSR approach according to the ISO 26000 standard with the aim of eventually obtaining a label in order to continue our growth while bringing positive change for people and the planet.
Two years ago, Valbiotis joined the Gaïa-Index, the French benchmark index for Small & MidCaps in terms of ESG, a subsidiary of EthiFinance and a player in the ESG (Environment, Social and Governance) rating of SMEs and ETIs listed French.
Gaïa Research assesses companies according to a benchmark of approximately 170 criteria for France, divided into 4 pillars: Environment, Social, Governance and External Stakeholders (ESG-PPE). These criteria make it possible to assess the extent to which sustainable development and long-term issues are taken into account in the strategy of economic players, and to measure their progress.
Valbiotis is a Research & Development company committed to scientific innovation to prevent and combat metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize health by developing a new class of health nutrition products intended to reduce the risk of major metabolic diseases, based on a multi-target strategy enabled by the use of plant resources. land and sea.
Its products are intended to be licensed to players in the health sector.
Created in early 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has set up three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec (Canada).
Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has also obtained the status of “Young Innovative Company” and has received significant financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a company eligible for PEA-PME.
For more information on Valbiotis, visit: www.valbiotis.com
ISIN Code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational assumptions and on the information available to Valbiotis to date. However, this does not in any way constitute a guarantee of future performance, and these projections may be affected by changes in economic and financial market conditions, as well as by certain risks and uncertainties, in particular those described in the Universal Registration Document. of Valbiotis approved by the Autorité des marchés financiers (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com). This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation to buy or subscribe to shares or financial securities of Valbiotis in any country whatsoever.